MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.320
-0.120
-3.49%
After Hours: 3.320 0 0.00% 16:00 07/10 EDT
OPEN
3.420
PREV CLOSE
3.440
HIGH
3.439
LOW
3.290
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
4.459
52 WEEK LOW
0.7200
MARKET CAP
351.92M
P/E (TTM)
-11.2162
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MEIP stock price target is 9.44 with a high estimate of 13.00 and a low estimate of 5.50.

EPS

MEIP News

More
MEI Pharma (MEIP) Stock Takes a Hit but This Analyst Keeps the Faith
SmarterAnalyst · 5d ago
MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm
PR Newswire · 6d ago
66 Biggest Movers From Thursday
Gainers GEE Group, Inc. (NYSE: JOB) shares climbed 199.9% to close at $1.54 on Thursday after the company eliminated over $47 million in debt and mezzanine financing.
Benzinga · 6d ago
Why MEI Pharma Is Tanking 15.3% Today
Motley Fool · 07/02 17:25
NUS, CPST, SOLO and MEIP among midday movers
Seeking Alpha - Article · 07/02 16:42
Morning Market Stats in 5 Minutes
Movers Indices • S&P 500 ETF (NYSE:SPY) increased 1.21% to $314.34. • Nasdaq ETF (NASDAQ:QQQ) increased 1.04% to $253.09. • Dow Jones Industrial Average ETF (NYSE:DIA) rose 1.50% to $261.23.
Benzinga · 07/02 13:46
Swiss pharma Helsinn, MEI scrap blood cancer therapy trial
Reuters · 07/02 12:26
Helsinn, MEI Pharma Discontinue Phase 3 Study With Pracinostat In Acute Myeloid Leukemia After Completing Interim Analysis, Results Showed Study Was Unlikely To Meet Primary Endpoint
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing potential new
Benzinga · 07/02 11:03

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About MEIP

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.